Literature DB >> 25846084

Non-inferiority trials: why oncologists must remain wary.

Mauricio Burotto1, Vinay Prasad1, Tito Fojo2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25846084     DOI： 10.1016/S1470-2045(15)70129-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  10 in total

1.  [Accelerated partial breast irradiation using interstitial multicatheter brachytherapy: A valid treatment option for breast cancer patients with a low-risk profile?].

Authors:  David Krug
Journal:  Strahlenther Onkol       Date:  2016-02       Impact factor: 3.621

Review 2.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

3.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

Review 4.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

5.  The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology.

Authors:  Ismail Jatoi; Mitchell H Gail
Journal:  JAMA Oncol       Date:  2020-03-01       Impact factor: 31.777

6.  Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

Authors:  Maha Hussain; Catherine Tangen; Celestia Higano; Nicholas Vogelzang; Ian Thompson
Journal:  J Clin Oncol       Date:  2015-11-09       Impact factor: 44.544

Review 7.  Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.

Authors:  A Aggarwal; T Fojo; C Chamberlain; C Davis; R Sullivan
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

8.  Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.

Authors:  Bishal Gyawali; Frazer A Tessema; Emily H Jung; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2019-08-02

9.  Surgical clinical trials with non-inferiority design: a cross-sectional bibliometric analysis.

Authors:  Chi Shu; Bin Huang; Ding Yuan; Yi Yang; Xiaojiong Du; Yazhou He; Xin Chen; Jichun Zhao
Journal:  Ann Transl Med       Date:  2021-08

Review 10.  Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.

Authors:  Per-Anders Abrahamsson
Journal:  Asian J Urol       Date:  2017-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.